

Date: 12.02.2025

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001.

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 12.02.2025**Ref: Regulation 30 and 33 along with Schedule III of SEBI(LODR) Regulations, 2015**

With reference to the subject cited, this is to inform the exchanges that at the Board Meeting of Sangam Healthcare Products Limited held on Wednesday, 12.02.2025 at 04.00 P.M at the registered office of the company, approved the following items of business:


1. Un-Audited Financial results for the quarter ended 31.12.2024. (enclosed).
2. Limited Review Report for the quarter ended 31.12.2024. (enclosed)

The meeting concluded at 4.30 P.M.

This is for your information and records.

Thanking You,

For and on Behalf of the
Sangam Healthcare Products Limited


A. Bala Gopal
Chairman and Managing Director
(DIN: 07087331)



SANGAM HEALTH CARE PRODUCTS LIMITED

205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DEC 31, 2024


(Rs. In Lakhs)

Particulars	Quarter ended			For the period ended		Year Ended
	31-12-2024	31-12-2023	30-09-2024	31-12-2024	31-12-2023	31-03-2024
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1 Income from Operations						
(a) Net Sales/Income from Operations	286.65	353.29	361.96	984.67	997.12	1,210.84
(b) Other Income-	-	-	-	-	-	-
Total Income	286.65	353.29	361.96	984.67	997.12	1,210.84
2 Expenditure						
(a) Cost of Raw material consumed	163.91	170.99	228.03	584.68	529.12	626.38
(b) Purchase of stock-in-trade	-	-	-	-	-	-
(c) Change in inventories of Finished Goods Works-in Progress and Stock in Trade	-	-	-	-	-	-
(d) Employees Benefit Expenses	45.58	40.49	48.59	148.83	132.73	190.14
(e) Finance Cost	0.03	0.56	0.01	0.06	1.03	2.08
(e).Depreciation and Amortization Expenses	30.43	30.43	30.43	91.29	91.29	121.85
(f). Other Expenditure	35.82	55.10	47.67	133.60	158.89	250.42
Total Expenses	275.77	297.57	354.72	958.46	913.06	1,190.87
3 Profit from Operations before Extraordinary Items and Exceptional Items (1-2)	10.88	55.71	7.24	26.22	84.06	19.97
4 Exceptional Items	-	-	-	-	-	-
9 Profit / (Loss) from Ordinary Activities before tax (7+8)	10.88	55.71	7.24	26.22	84.06	19.97
10 Current tax	-	-	-	-	-	-
Deferred tax	-	-	-	-	-	(21.86)
11 Net Profit (+)/Loss(-) from Ordinary Activities After Tax (9-10)	10.88	55.71	7.24	26.22	84.06	41.83
12 Paid up equity share capital (no of shares) (face value of the share Rs.10/-)	1486.07	1486.07	1486.07	1,486.07	1,486.07	1,486.07
13 Reserves excluding revaluation reserves	NIL	NIL	NIL	NIL	NIL	NIL
14 Earning Per Share (EPS)	0.07	0.37	0.05	0.02	0.06	0.28
a) Basic and diluted Eps before Extraordinary (not to be annualized)						
b) Basic and diluted Eps after Extraordinary (not to be annualized)						

- Note :
- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at the meeting held on 12-02-2025
 - The Limited Review of the Financials has been carried out by the Statutory Auditors of the Company in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 - Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.
 - W.r.t Order No LIST/COMP/ MR/1454/2024-25, Company has been delisted by BSE w.e.f November 28th, 2024 due to Non Compliance of certain requirements. However, Company is in the process of listing.

For Sangam Health Care Products Limited

A. K. Srinivas



Place : Hyderabad
Date: 12-02-2025

Chairman and Managing Director



LIMITED REVIEW REPORT

To,
The Board of Directors,
SANGAM HEALTH CARE PRODUCTS LIMITED

We have reviewed the accompanying statement of Un-Audited Financial Results of **SANGAM HEALTH CARE PRODUCTS LIMITED** for the quarter ended **31st December, 2024** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 12-02-2025

For M M REDDY & CO.,
Chartered Accountants
Firm Reg No.: 010371S

M. Madhusudhana Reddy
Partner
Membership No. 213077
UDIN: 25213077BMIHOP1159

